EP. 1: Embracing New Therapies in Schizophrenia Management: Introductions
In part 1 of 5, panel moderator gives an overview of the Special Report focusing on the approval of Xanomeline and tropism chloride capsules for schizophrenia.
EP. 2: Mechanism of Action of Xanomeline and Trospium Chloride Capsules in Schizophrenia
In part 2 of 5, experts discuss the unique mechanism of xanomeline and trospium choloride capsules for the treatment of schizozphrenia.
EP. 3: Applying EMERGENT Trial Results to Real-World Clinical Practice for Schizophrenia
In part 3 of 5, experts discuss the pivotal trials evaulating xanomeline and trospium chloride capsules (Cobenfy) for schizophrenia.
EP. 4: Balancing the Benefits and Risks of Xanomeline and Trospium Chloride Capsules
In part 4 of 5, experts discuss medication adherence to schizophrenia treatments, particularly of xanomeline and trospium choloride capsules for schizophrenia.
EP. 5: Unmet Needs, Future Research in Schizophrenia and Muscarinic Agonists
In part 5 of 5, experts discuss ongoing unmet needs and future research priorities in schizophrenia management.
